Abstracts tagged "systemic sclerosis and treatment"

Abstract Number: 800 • 2018 ACR/ARHP Annual Meeting
Assessment of Recent Evidence to Support Treatment Recommendations in Patients with SSc-ILD
Anna-Maria Hoffmann-Vold¹, Toby Maher², Edward Philpot³, Ali Ashrafzadeh⁴, Diwakar Jha⁵, Margarida Alves⁶ and Oliver Distler⁷, ¹Oslo University Hospital, Oslo, Norway, ²Royal Brompton Hospital, London, United Kingdom, ³IQVIA, Durham, NC, ⁴IQVIA, Los Angeles, CA, ⁵IQVIA, Gurugram, India, ⁶Boehringer Ingelheim International GmbH, Ingelheim, Germany, ⁷Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: Systemic Sclerosis (SSc) is a chronic autoimmune disease characterized by fibrosis of skin and internal organs with an estimated worldwide prevalence of 110-430 cases/million.…
Abstract Number: 1724 • 2018 ACR/ARHP Annual Meeting
Effectiveness and Safety of Rituximab for the Treatment of Refractory Systemic Sclerosis Associated Calcinosis: A Case Series
Francisco Javier Narváez¹, Juan Pablo Pirola², Judit Lluch³, Pablo Juárez³, Isabel Morales³ and Joan Miquel Nolla³, ¹Rheumatology Department, Hospital de Bellvitge. Barcelona. Spain, L’Hospitalet de Llobregat, Spain, ²Rheumatology, Hospital Privado Centro Médico de Córdoba, Cordoba, Argentina, ³Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: To analyze the effectiveness and safety of rituximab (RTX) for the treatment of refractory systemic sclerosis (SSc)–associated calcinosis. Methods: We undertook an observational study…
Abstract Number: 1877 • 2018 ACR/ARHP Annual Meeting
Specific Pneumoproteins Predict Progression of Interstitial Lung Disease in Systemic Sclerosis Patients Undergoing Treatment with Immunosuppression
Elizabeth R. Volkmann¹, Donald P. Tashkin¹, Masataka Kuwana², Ning Li³, Julio Charles⁴, Faye N. Hant⁵, Galina S. Bogatkevich⁶, Tanjina Akter⁶, Michael Roth⁷, Hyun J. Grace Kim⁸, Jonathan Goldin⁹, Dinesh Khanna¹⁰, Philip J. Clements¹¹, Daniel E. Furst⁷, Robert Elashoff¹², Rick Silver¹³ and Shervin Assassi¹⁴, ¹University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ³Biomathematics, University of California, Los Angeles, Los Angeles, CA, ⁴University of Texas Health Science Center at Houston, Houston, TX, ⁵Rheumatology, Medical University of South Carolina, Charleston, SC, ⁶Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC, ⁷Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁸Department of Radiology, David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁹Department of Radiological Sciences at UCLA, University of California, Los Angeles, David Geffen School of Medicine, Santa Monica, CA, ¹⁰Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ¹¹Medicine, University of California, Los Angeles, Los Angeles, CA, ¹²University of California, Los Angeles, Los Angeles, CA, ¹³Rheumatology, Medical University of SC, Charleston, SC, ¹⁴University of Texas McGovern Medical School, Houston, TX
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in systemic sclerosis (SSc). While some SSc-ILD patients are stable or improve with immunosuppressive…
Abstract Number: 2708 • 2018 ACR/ARHP Annual Meeting
Current Management of Early Diffuse Cutaneous Systemic Sclerosis in US Scleroderma Centers
Rebecca B. Blank¹, Jessica K. Gordon², Jackie Szymonifka³, Shervin Assassi⁴, Elana J. Bernstein⁵, Flavia V. Castelino⁶, Robyn T. Domsic⁷, Faye N. Hant⁸, Monique Hinchcliff⁹, Kate Homer¹⁰, Ami A. Shah¹¹, Victoria Shanmugam¹², Virginia D. Steen¹³, Tracy M. Frech¹⁴ and Dinesh Khanna¹⁵, ¹Internal Medicine, New York Presbyterian-Weill Cornell Hospital, New York, NY, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Hospital for Special Surgery, New York, NY, ⁴University of Texas McGovern Medical School, Houston, TX, ⁵Rheumatology, Columbia University, New York, NY, ⁶Rheumatology, Harvard Medical School, Boston, MA, ⁷Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁸Rheumatology, Medical University of South Carolina, Charleston, SC, ⁹Division of Rheumatology, Northwestern University Medical School, Chicago, IL, ¹⁰Department of Internal Medicine, Rheumatology Division, Scleroderma Program, University of Michigan, Ann Arbor, MI, ¹¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ¹²Rheumatology, The George Washington University, Washington, DC, ¹³Rheumatology, MedStar Georgetown University Hospital, Washington, DC, ¹⁴Division of Rheumatology, University of Utah, Salt Lake City, UT, ¹⁵Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI
Background/Purpose: Standard treatment for the diverse aspects of diffuse cutaneous systemic sclerosis (dcSSc) is not yet well defined although experts have described therapeutic algorithms. The…
Abstract Number: 749 • 2017 ACR/ARHP Annual Meeting
Treatment with Cyclophosphamide for Systemic Sclerosis-Interstitial Lung Disease Does Not Lead to a Sustained Improvement in Lung Function in Two Independent Cohorts
Elizabeth R. Volkmann¹, Donald P. Tashkin¹, Myung Sim¹, Ning Li², Dinesh Khanna³, Michael Roth⁴, Philip J. Clements⁴, Anna-Maria Hoffmann-Vold⁵, Daniel E. Furst¹, Grace Kim⁶, Jonathan Goldin¹ and Robert Elashoff⁷, ¹University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²Biomathematics, University of California, Los Angeles, Los Angeles, CA, ³University of Michigan, Ann Arbor, MI, ⁴Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁵Oslo University Hospital, Oslo, Norway, ⁶Radiology, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁷University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Compared with placebo, treatment with cyclophosphamide (CYC) improved lung function in patients with systemic sclerosis-related interstitial lung disease (SSc-ILD) after 1 year in Scleroderma…
Abstract Number: 943 • 2017 ACR/ARHP Annual Meeting
The Course of the Forced Vital Capacity during Treatment for Systemic Sclerosis-Related Interstitial Lung Disease Predicts Long-Term Survival in 2 Independent Cohorts
Elizabeth R. Volkmann¹, Donald P. Tashkin¹, Myung Sim¹, Dinesh Khanna², Michael Roth³, Philip J. Clements³, Daniel E. Furst¹, Lynette Keyes-Elstein⁴, Ashley Pinckney⁴, Ellen Goldmuntz⁵, Robert Elashoff⁶ and Keith Sullivan⁷, ¹University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²University of Michigan, Ann Arbor, MI, ³Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁴Rho Federal Systems, Inc., Chapel Hill, NC, ⁵NIAID, NIH, Bethesda, MD, ⁶University of California, Los Angeles, Los Angeles, CA, ⁷Duke University, Durham, NC
Background/Purpose: While prior observational studies have identified predictors of mortality in systemic sclerosis-interstitial lung disease (SSc-ILD), no studies have evaluated predictors of long-term mortality in…
Abstract Number: 2692 • 2017 ACR/ARHP Annual Meeting
Vitamin D Deficiency in Systemic Sclerosis Patients: Relations with Multiple Clinical Parameters and Standard Treatment
Amelia Chiara Trombetta¹, Vanessa Smith², Emanuele Gotelli¹, Massimo Ghio¹, Sabrina Paolino¹, Carmen Pizzorni³, Amber Vanhaecke⁴, Barbara Ruaro⁵, Alberto Sulli³ and Maurizio Cutolo³, ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino, Genoa, Italy, Genoa, Italy, ²Faculty of Internal Medicine, Ghent University, Ghent, Belgium, ³Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, IRCCS Policlinico San Martino, University of Genoa, Genoa, Italy, Genoa, Italy, ⁴Department of Rheumatology, Ghent University Hospital, Ghent University, Ghent, Belgium, Gent, Belgium, ⁵Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, Genoa, Italy, Genoa, Italy
Vitamin D Deficiency In Systemic Sclerosis Patients: Relations With Multiple Clinical Parameters and Standard TreatmentBackground/Purpose : In SSc patients, low 25-hydroxyvitamin D (25(OH)D) serum concentrations have…
Abstract Number: 2889 • 2017 ACR/ARHP Annual Meeting
Aminaphtone Ameliorates Clinical Symptoms and Increases Skin Blood Perfusion in Patients with Both Primary and Secondary Raynaud Phenomenon: A Six-Month Open Study
Alberto Sulli¹, Maurizio Cutolo², Carmen Pizzorni², Sabrina Paolino², Elisa Alessandri², Emanuele Gotelli² and Barbara Ruaro², ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino, Genoa, Italy, Genova, Italy, ²Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino, Genoa, Italy, Genoa, Italy
Background/Purpose: Current treatments for Raynaud's phenomenon (RP) have limited efficacy, which was mainly demonstrated by physician/patient reported outcomes. Aminaphtone is a vasoactive drug recently suggested…
Abstract Number: 1896 • 2016 ACR/ARHP Annual Meeting
Efficacy of Pulmonary Arterial Hypertension-Specific Drugs Combination Therapy in Survival of Patients with Pulmonary Arterial Hypertension Associated with Systemic Sclerosis and Other Connective Tissue Diseases
Sumiaki Tanaka¹, Yu Matsueda¹, Gakuro Abe², Jun Okada³ and Shunsei Hirohata¹, ¹Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan, ²Kitasato University School of Medicine, Sagamihara, Japan, ³Nutritional management, Kitasato Junior Collage of health and Hygienic Sciences, Minami-Uonuma, Japan
Background/Purpose: Survival of patients with pulmonary arterial hypertension (PAH) associated with connective tissue disease (CTD), especially systemic sclerosis (SSc), is poorer than that of patients…
Abstract Number: 2069 • 2016 ACR/ARHP Annual Meeting
Dipeptidyl-Peptidase-4 (DPP4) Positive Fibroblast Subpopulation Promotes Fibrosis and Are a Molecular Target for Treatment of Fibrosis
Alina Soare^1,2, Simon Rauber³, Thomas Wohlfahrt¹, Clara Dees⁴, Ruifang Liang⁴, Yun Zhang¹, Chih-Wei Chen¹, Andreas Ramming⁵, Oliver Distler⁶, Carina Mihai⁷, Georg Schett⁴ and Joerg HW Distler⁴, ¹Department of Internal Medicine 3 and Institute for Clinical Immunology, Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Carol Davila University of Medicine and Pharmacy, Internal Medicine and Rheumatology Department, Cantacuzino Clinical Hospital, Bucharest, Romania, ³Department of Internal Medicine 3, Rheumatology and Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁴Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ⁵Department of Internal Medicine 3, Rheumatology and Immunology, Department of Internal Medicine 3, Rheumatology and Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁶Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁷Department of Internal Medicine and Rheumatology, Carol Davila University of Medicine and Pharmacy, Cantacuzino Hospital, Bucharest, Romania
Background/Purpose: Dipeptidyl-peptidase-4 (DPP4) has been recently shown to identify a distinct dermal lineage with intrinsic fibrogenic potential and its targeted inhibition leads to reduced scar…
Abstract Number: 2888 • 2016 ACR/ARHP Annual Meeting
Usefulness of Bosentan in the Prevention of Pulmonary Hypertension in Patients with Systemic Sclerosis
Ivan Castellví¹, Carmen Pilar Simeón², Monica Paola Sarmiento¹, Alfredo Guillen², Cesar Diaz-Torné³, Josep Maria De Llobet Zubiaga¹, Jordi Casademont⁴ and Vicent Fonollosa², ¹Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain, ²Internal Medicine, Hospital Universitari Vall d'Hebron, Barcelona, Spain, ³Rheumatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁴Internal Medicine, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain
Background/Purpose: Systemic sclerosis (SSc) is a systemic autoimmune disease in which the damage of microcirculation is critical to develop the disease. In SSc, vascular complications…
Abstract Number: 2913 • 2016 ACR/ARHP Annual Meeting
Four Year Effects of Combined Bosentan and Iloprost Treatment on Nailfold Absolute Capillary Number, Fingertip Blood Perfusion and Clinical Status, in Systemic Sclerosis Patients
Amelia Chiara Trombetta¹, Carmen Pizzorni², Barbara Ruaro³, Sabrina Paolino³, Alberto Sulli², Vanessa Smith⁴ and Maurizio Cutolo³, ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, Genova, Italy, ²Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, IRCCS A.O.U. San Martino-IST, University of Genova, Genoa, Italy, Genova, Italy, ³Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, IRCCS A.O.U. San Martino-IST, University of Genova, Genoa, Italy, Genoa, Italy, ⁴Department of Rheumatology, Ghent University Hospital, Ghent University, Ghent, Belgium
Background/Purpose: In systemic sclerosis (SSc), microvascular damage progresses from capillary dilation to capillary loss and reactive angiogenesis, as detectable by nailfold videocapillaroscopy (NVC) [1]. The…
Abstract Number: 3247 • 2016 ACR/ARHP Annual Meeting
Safety and Efficacy of Belimumab with Background Mycophenolate for Early Diffuse Cutaneous Systemic Sclerosis: A Randomized, Placebo Controlled, Pilot Trial
Jessica K. Gordon¹, Eliza Pelrine², Yuo-Yu Lee³, Cynthia Magro⁴, Elana J. Bernstein⁵, Horatio F. Wildman⁶ and Robert F. Spiera¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Epidemiology and Biostatistics, Hospital for Special Surgery, New York, NY, ⁴Pathology, Weill Cornell Medical College, New York, NY, ⁵Department of Medicine, Division of Rheumatology, Columbia University, New York, NY, ⁶Dermatology, Weill Cornell Medical College, New York, NY
Background/Purpose: Abnormalities of B cell function are part of the pathogenesis of systemic sclerosis (SSc), and B-lymphocyte stimulator (BLyS) is increased in the serum and…
Abstract Number: 848 • 2015 ACR/ARHP Annual Meeting
Nitroglycerin Patch Application in Systemic Sclerosis: Evaluation By Laser Doppler Imaging
Georgiana Bentea, Aurelien Wauters, Jean-Claude Wautrecht and Elie Cogan, Erasme Hospital, Brussels, Belgium
Background/Purpose: Systemic sclerosis (SSc) is a complex autoimmune disease, commonly associated with Raynaud phenomenon (RP). The aim of this study was to characterize the microvascular…
Abstract Number: 1879 • 2015 ACR/ARHP Annual Meeting
Immunosuppressive “Routine”� Treatment of SSc Patients with Limited Cutaneous Involvement and Interstitial Lung Disease
Dörte Huscher¹, Sabine Adler², Elise Siegert³, Giuseppina Abignano⁴, Yannick Allanore⁵, Jerome Avouac⁶, Kerstin Becker⁷, Laszlo Czirjak^8,9, Francesco Del Galdo¹⁰, Christopher P. Denton¹¹, Oliver Distler¹², Ivan Foeldvari¹³, Beata Garay-Toth¹⁴, Serena Guiducci¹⁵, Veronika K. Jaeger¹⁶, Veronika Lóránd⁹, Marco Matucci-Cerinic¹⁷, Britta Maurer¹⁸, Ulf Müller-Ladner¹⁹, Svetlana I. Nihtyanova²⁰, Ingo H. Tarner²¹, Gabriele Valentini²², Serena Vettori²³, Ulrich A. Walker²⁴ and Gabriela Riemekasten²⁵, ¹Charité-University Hospital and German Rheumatism Research Centre, Berlin, Germany, ²Rheumatology, Immunology, Allergology, University Hospital Bern, Bern, Switzerland, ³Rheumatology and Clinical Immunology, Charité – University Hospital, Berlin, Berlin, Germany, ⁴Clinical and Experimental Medicine, Second University of Naples, Napoli, Italy, ⁵Department of Rheumatology A, Paris Descartes University, Cochin Hospital, Paris, France, ⁶Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, ⁷Rheumatology and Clinical Immunology, Charité University Hospital, Berlin, Germany, ⁸Rheumatology, Pecs, Hungary, ⁹Rheumatology and Immunology Medical School, University of Pécs, Pécs, Hungary, ¹⁰Scleroderma Group, Leeds Institute of Molecular Medicine, Leeds, United Kingdom, ¹¹Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, ¹²Department of Rheumatology, Research of Systemic Autoimmune Diseases, University Hospital Zurich, Zurich, Switzerland, ¹³Hamburger Zentrum für Kinder-und Jugendrheumatologie, Hamburg, Germany, ¹⁴FESCA, Budapest, Hungary, ¹⁵Rheumatology, University of Florence, Florence, Italy, ¹⁶Department of Rheumatology, University Hospital Basel, Basel, Switzerland, ¹⁷Dept of Medicine/Div of Rheum, University of Florence, Firenze, Italy, ¹⁸r, University Hospital Zurich, Zurich, Switzerland, ¹⁹Internal Medicine and Rheumatology, Justus-Liebig-University of Giessen, Kerckhoff-Klinik, Bad Nauheim, Germany, ²⁰Rheumatology, UCL Division of Medicine, London, United Kingdom, ²¹Rheumatology and Clinical Immunology, Justus-Liebig-University of Giessen, Kerckhoff-Klinik, Bad Nauheim, Germany, ²²Internal and Experimental Medicine, Rheumatology Unit, Second University of Naples, Naples, Italy, ²³Department of Internal and Experimental Medicine, Rheumatology Unit, Second University of Naples, Naples, Italy, ²⁴Rheumatology, Systemic Sclerosis, Basel, Switzerland, ²⁵Clinic of Rheumatology, University of Luebeck, Lübeck, Germany
Background/Purpose: Interstitial lung disease (ILD) represents one of the most frequent causes of death in systemic sclerosis (SSc) patients. Yet, there are no approved drugs…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].